Non-exclusive pharmaceutical discount agreement for Denosumab (Prolia) under open-house model
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Denosumab Prolia (ATC-Code nach WHO: M05BX04)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No guaranteed volumes; actual demand is unknown and may be low, affecting revenue predictability.
The contracting authority may terminate the open-house procedure early if exclusive agreements are concluded, ending al...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Non-exclusive discount agreement for pharmaceutical products with active substance Denosumab (Prolia)
- Open-house model allowing continuous participation
Show full summary
Non-exclusive pharmaceutical discount agreement under an open-house model for the active substance Denosumab (Prolia) with AOK PLUS. The agreement is open to all pharmaceutical entrepreneurs meeting eligibility criteria, with no guaranteed volumes and no exclusive rights. The contract runs until May 31, 2027, with flexible submission deadlines.
Risks
No guaranteed volumes; actual demand is unknown and may be low, affecting revenue predictability.
The contracting authority may terminate the open-house procedure early if exclusive agreements are concluded, ending al...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs.18 AMG
Eligibility
- No exclusion grounds under §§123, 124 GWB (self-declaration required)
Administrative
- Compliance with EU sanctions against Russia (self-declaration required)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive pharmaceutical discount agreement for Denosumab (Prolia) under open-house model
Non-exclusive discount agreement for Denosumab (Prolia) including biosimilars and imports. Open-house model with no negotiation or exclusivity. Unknown demand; no minimum volumes guaranteed.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Denosumab Prolia (ATC-Code nach WHO: M05BX04)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 30 Jun 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 451344-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No guaranteed volumes; actual demand is unknown and may be low, affecting revenue predictability.
The contracting authority may terminate the open-house procedure early if exclusive agreements are concluded, ending al...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications